The use of novel psychoactive substances (NPS) or ‘legal highs’ is an emerging issue worldwide. There is rising concern around the risks of NPS and the detrimental effects on individuals’ mental health. How can you as a nurse identify and manage risks around NPS in your everyday nursing practice?

Introduction

Novel psychoactive substances (NPS) or the so-called ‘legal highs’ are emerging rapidly worldwide, as are concerns about NPS abuse. NPS have been a growing trend over the past decade for a number of reasons, including difficulties detecting them in routine urine drug screens, legal loopholes, easy access through the internet and low cost.1 Labelling these drugs as ‘herbal highs’ or ‘legal highs’ is misleading as there is nothing natural about these synthetic and untested drugs and also currently none of them are legal in New Zealand.2 But there has been an explosion in numbers of NPS worldwide with the European Monitoring Centre for Drugs and Drug Addiction (EMCDDA) reporting this year that it is now monitoring 560 NPS and 98 new substances that were reported for the first time in 2015 and 101 in 2014.3 There are several typical categories of NPS drugs including synthetic cathinones (e.g. mephedrone and MDPV), plant-based NPS (e.g. khat and salvia divinorum), synthetic cannabinoids (e.g. ‘Spice’, ‘Kronic’ and ‘K2’), and ‘party’ drugs like benzylpiperazine (BZP).

Synthetic drugs can be taken through insufflation (snorting), oral ingestion and rectal insertion, as well as being taken intravenously, intramuscularly and subcutaneously. These drugs are considered to have an effect on mental health wellbeing. Identified mental health symptoms that can result from NPS use are low mood, confusion, and anxiety.4 The European Monitoring Centre for Drugs and Drug Addiction (EMCDDA)4 identified synthetic cannabinoids as prominent in affecting mood and perception and that intoxications can cause agitation, tachycardia, and arterial hypertension. The centre says that synthetic cannabinoids are 100 times more powerful than traditional strains of cannabis.4 The EMCDDA also identified synthetic cathinones as hallucinogenic stimulants with cardiovascular and psychiatric side effects. The number of deaths involving NPS increased by 15 per cent in 2013 in the United Kingdom, with 60 deaths, up from 52 deaths in 2012.5 New Zealand attempted temporary bans on different NPS before passing the Psychoactive Substances Act in 2013, which puts the responsibility on NPS producers or importers to prove they are low risk. At present no NPS products are legally available for sale in New Zealand,6 but the the ingredients for making illicit drugs are still available for purchase on untraceable internet sites so access to NPS continues.

Detection of NPS use can be difficult as adult users – who usually present with agitation, cardiovascular and psychiatric symptoms – can often pass urine drug screening due to the lack of detectable metabolites. To further complicate matters, the molecular makeup of NPS drugs can be changed slightly to make detection through urine drug screening tests even more difficult.7 It has been suggested that health professionals, for example, in emergency departments, primary health and mental health services, need to be made aware of the growing levels of NPS misuse so that it can be identified and treated accordingly.8

Examples of NPS and the risks they could pose to the people you nurse

It is useful for nurses to have an understanding of the potential risks of NPS. Nurses also need to maintain a therapeutic relationship that is respectful of the individual’s choices, experiences and expertise.9,10,11 This section looks at some of the NPS currently available.

Synthetic cathinones

Mephedrone is one of a group of synthetic cathinone drugs that are chemically similar to amphetamines. Another is methylenedioxypyrovalerone (MDPV). Synthetic cathinones can result in the stimulation of psychosis, neurological and other health complications. Mental health professional intervention is needed for people with mental health problems as a result of mephedrone misuse.

Synthetic cathinones have been found to have similar effects to psychostimulatory drugs of misuse including cocaine, amphetamine and MDMA (ecstasy). Psychiatric symptoms as a result of mephedrone/cathinone misuse include aggression, agitation, anhedonia, anxiety, confusion, delusions, depression, dysphoria, irritability, loosening of association, mental fatigue, panic attacks, paranoia, perceptual distortion, psychosis, self-mutilation, suicidal
thoughts/suicide and visual and auditory hallucinations. Addictive symptoms identified include tolerance, craving and withdrawal syndrome. 19

‘N-Bomb’ or NBOMe
The psychedelic drug commonly known as ‘N-Bomb’ (25I-NBOMe, 2C-I-NBOMe) is a powerful hallucinogen that has been prevalent in New Zealand since 2012. 14 N-Bomb’s high potency increases risks of toxicity in small doses. Common routes of administration include sublingual, buccal, and nasal/ intranasal. 11

The hallucinogenic effects of N-Bombs mimic LSD and can last between six and 10 hours and include feelings of euphoria, mental and physical stimulation, a pleasant or positive change in consciousness and unusual body sensations. Risks include tachycardia, hypertension, pyrexia, agitation, hallucinations, seizures and death. There have been media reports in New Zealand of renal and cardiovascular complications following use and overseas there have been a number of N-Bomb-related deaths. 14

Spice and other synthetic cannabinoids
The misuse of ‘Spice’ or synthetic cannabinoids is increasing among teenagers and adults. Spice has over 220 compounds in various different combinations or brands. 16 There is also a risk of Spice causing psychopathological disturbances, namely psychosis, causing what is known as “Spiceophrenia”. Spice can affect a person’s physical state and can trigger vomiting, seizures, tachycardia, mydriasis, hypertension, confusion and restlessness. Mental health symptoms include delusions, paranoia, disorganised thought and visual and auditory hallucinations. Fluctuating mood, anxiety, perception, thinking, memory, and attention is common. Agitation, panic, dysphoria, psychosis and bizarre behaviour are also common. 17

Why may people who experience MH issues use NPS?
There are various reasons for the prevalence of people with mental health problems abusing illicit substances like NPS. This includes the cheap availability of NPS, accessibility and peer pressure. 1

Also, according to Ponizovsky et al, people with co-existing problems are more at risk of non-adherence to prescribed medication and therefore more prone to relapse, rehospitalisation, and illicit drug and alcohol use. One recent research study talks about mental health service users using illicit drugs to control their distressing symptoms, or to “relax” and to get “high”. 19 The findings of this empirical study suggest that substance use was related to controlling emotional states, anxiety, and depression. Alcohol was seen as less harmful than cannabis and other psychoactive compounds in the perception of the mentally ill substance user. Counteracting psychiatric medication side effects was also identified as a reason, alongside controlling psychotic states, i.e. managing auditory hallucinations by smoking more cannabis. So nurses should be aware that some clients may ‘manage’ mental health symptoms with illicit drugs and alcohol. Mental health professionals use a range of patient-centred and focused risk assessments that have been formulated specifically for people with co-existing problems. 19

One harm reduction approach to tackling NPS or other substance misuse, that can be done in non-specialist addiction settings like primary health, is using a brief assessment tool to assess whether alcohol or drug problems are at the ‘social or harmless use’ end of the continuum or the ‘moderate to severe’. This helps identify the level of intervention needed with mild problems usually just needing a brief intervention to reduce use to safe levels, while ‘moderate to severe’ problems require a comprehensive assessment and management plan. 19

Co-existing problem approaches
The New Zealand guidelines for the assessment and management of co-existing problems take a client-centred approach. The guidelines set out seven key principles, including screening all clients presenting in mental health and addiction services for CEP and, if positive, undertaking a comprehensive assessment that gives equal weight to both mental health and substance use problems. Also emphasised is safety, stabilisation, engaging with clients by developing a ‘trusting, empathetic and non-judgemental therapeutic

<table>
<thead>
<tr>
<th>TIPS FOR AWARENESS AND DETECTION OF NPS USE</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>NPS drug</strong></td>
</tr>
<tr>
<td>Stimulation ‘legal highs’</td>
</tr>
<tr>
<td>These act in similar ways to cocaine, ecstasy or amphetamines.</td>
</tr>
<tr>
<td>Examples include: benzylpiperazine, Benzo Fury, party powder, mephedrone, TNT, legal ecstasy and legal speed.</td>
</tr>
<tr>
<td>Sedative or downer ‘legal highs’</td>
</tr>
<tr>
<td>These work and act in a similar way to benzodiazepines.</td>
</tr>
<tr>
<td>They include: Spice, Kronic (and other synthetic cannabinoids), GHB, VB (ex-Fast Lane – legal coke), Mello Man (opium effect), Space Trips (LSD substitute), Hi-Octane (energy pills), TNT (speed), Big Daddy (ecstasy) and Sex Intense pills (sex party pills).</td>
</tr>
<tr>
<td>Psychedelic or hallucinogenic ‘legal highs’</td>
</tr>
<tr>
<td>These have effects similar to those of magic mushrooms, LSD.</td>
</tr>
<tr>
<td>Examples include: ketamine, N-bomb, 3-MeO-PCP, Space Trips, Bubble Bud, Druids Fantasy, Space Cadets and Salvia divinorum.</td>
</tr>
</tbody>
</table>

Table: reference (Sisroon et al 2014)

**CO-EXISTING PROBLEMS**

Mental health problems are widely associated with substance misuse, including the use of legal highs. There are a range of terms used to describe this combination of problems, including dual diagnosis, but the term ‘co-existing substance use and mental health problems’, or co-existing problems (CEP) for short, is used in New Zealand with ‘co-existing’ chosen as it implies interaction more than ‘co-occurring’. CEP are highly prevalent in therapeutic settings in New Zealand with an estimated third to half of all tangata whaiora (service clients) in mental health settings likely to have current CEP and up to three-quarters of clients seeing addiction services. People with severe CEP experience higher rates of institutionalisation, more failed treatment attempts, poverty, homelessness and risk of suicide. 20

It is estimated that 40 per cent of people with psychosis also have substance misuse problems. People with co-existing substance use and mental health disorders have higher rates of unmet needs and a higher rate of relapse and hospitalisation than those who primarily have psychosis. 21

It has been identified that some people with psychosis commonly misuse non-prescribed medication to deal with persisting psychiatric symptoms, which ultimately exacerbate
‘Legal highs’ and mental health: raising nurse awareness

RECOMMENDED FURTHER RESOURCES

New Zealand Drug Foundation: Aimed at preventing and reducing harm from drug use and includes information on NPS used in New Zealand www.drugfoundation.org.nz

Psychoactive Substances Regulatory Authority: Information on New Zealand’s ‘legal highs’ regulation system http://psychoactives.health.govt.nz

NEPTUNE (Novel Psychoactive Treatment UK Network): guidance on managing harm from NPS http://goo.gl/XZ4W1

Toxin: National poisons information database www.toxinz.com

NICE (National Institute for Health and Care Excellence): UK site with pathway for psychosis with coexisting substance misuse http://www.nice.org.uk/CG63LH

FRANK: UK site offering ‘friendly, confidential drugs advice’: www.talktofrank.com/drug/n-bomb

About the authors:

David Solomon MSc, PG Cert HE, BSc (Hons), Fellow of Higher Education. Independent Prescriber; RMN.

Senior Lecturer, Nurse, Faculty of Health, Social Care and Education, Essex, Anglia Ruskin University.

Bernadette Solomon DHSc candidate, MSc (Applied Criminology), PG Cert HE, RMN. Professional Teaching Fellow, Faculty of Medical and Health Sciences. Mental Health and Addictions, The University of Auckland, New Zealand.

This article was peer reviewed by:

Daryl Deering RN PhD is a senior lecturer at the National Addiction Centre, the University of Otago.

Louise Leonard RN NP BA (Psych) MNR is a nurse practitioner working in alcohol and other drug addictions for Waikato District Health Board’s mental health and addiction services.

REFERENCES


